Prognostic Significance of Interim Response Evaluation during Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
暂无分享,去创建一个
C. Lee | Hyojin Park | Y. Youn | Jie Hyun Kim | J. Chun | Jun Won Kim | I. Lee | Yeona Cho | Jun Gi Yeom
[1] T. Mak,et al. The role of Hippo‐YAP signaling in squamous cell carcinomas , 2020, Cancer science.
[2] Lidong Wang,et al. Regulation of Hippo/YAP signaling and Esophageal Squamous Carcinoma progression by an E3 ubiquitin ligase PARK2 , 2020, Theranostics.
[3] K. Kitajima,et al. Assessment of tumor response to definitive chemoradiotherapy and prognosis prediction in patients with esophageal cancer judged by PET response criteria in solid tumors: multicenter study in Japan , 2020, Nuclear medicine communications.
[4] Xue Wu,et al. YAP1 amplification as a prognostic factor of definitive chemoradiotherapy in nonsurgical esophageal squamous cell carcinoma , 2019, Cancer medicine.
[5] Zhihua Wen,et al. Yes-associated protein (YAP) predicts poor prognosis and regulates progression of esophageal squamous cell cancer through epithelial-mesenchymal transition , 2019, Experimental and therapeutic medicine.
[6] Jan-Jakob Sonke,et al. Adaptive Radiotherapy for Anatomical Changes. , 2019, Seminars in radiation oncology.
[7] R. Yu,et al. Outcomes and prognostic factors for patients with cervical esophageal cancer undergoing definitive radiotherapy or chemoradiotherapy. , 2019, Bosnian journal of basic medical sciences.
[8] De-min Li,et al. Correlation between Bax gene polymorphisms and esophagus cancer , 2018, Oncology letters.
[9] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[10] Anhui Wang. Epidemiology of Esophageal Squamous Cell Carcinoma , 2018 .
[11] C. Hsieh,et al. Favorable versus unfavorable prognostic groups by post-chemoradiation FDG-PET imaging in node-positive esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[12] Wen-en Zhao,et al. Potent hydrazone derivatives targeting esophageal cancer cells. , 2018, European journal of medicinal chemistry.
[13] Jesper Lagergren,et al. Oesophageal cancer , 2017, The Lancet.
[14] M. Berry. Esophageal cancer: staging system and guidelines for staging and treatment. , 2014, Journal of thoracic disease.
[15] T. Borght,et al. A Systematic Review of the Predictive Value of 18FDG-PET in Esophageal and Esophagogastric Junction Cancer After Neoadjuvant Chemoradiation on the Survival Outcome Stratification , 2014, Journal of Gastrointestinal Surgery.
[16] J. Hwang,et al. Clinical Prognostic Factors for Locally Advanced Esophageal Squamous Carcinoma Treated after Definitive Chemoradiotherapy , 2013, Cancer research and treatment : official journal of Korean Cancer Association.
[17] E W Steyerberg,et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. , 2012, The New England journal of medicine.
[18] J. Ajani,et al. Nomograms for Prognostication of Outcome in Patients with Esophageal and Gastroesophageal Carcinoma Undergoing Definitive Chemoradiotherapy , 2012, Oncology.
[19] Lin-jun Tong,et al. Can 18F-fluorodeoxyglucose positron emission tomography predict responses to neoadjuvant therapy in oesophageal cancer patients? A meta-analysis , 2011, Nuclear medicine communications.
[20] R. M. Kwee. Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of 18F FDG PET: a systematic review. , 2010, Radiology.
[21] J. Ajani,et al. Patterns of care and locoregional treatment outcomes in older esophageal cancer patients: The SEER-Medicare Cohort. , 2009, International journal of radiation oncology, biology, physics.
[22] N. Khushalani. Cancer of the esophagus and stomach. , 2008, Mayo Clinic proceedings.
[23] P. Maingon,et al. Phase III trial of protracted compared with split-course chemoradiation for esophageal carcinoma: Federation Francophone de Cancerologie Digestive 9102. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] S. Kang,et al. Low Expression of Bax Predicts Poor Prognosis in Patients with Locally Advanced Esophageal Cancer Treated with Definitive Chemoradiotherapy , 2007, Clinical Cancer Research.
[25] F. Joubert,et al. Bax/Bcl-2 expression levels of 2-methoxyestradiol-exposed esophageal cancer cells. , 2005, Biomedical research.
[26] G. Noël,et al. INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III Trial of Combined-Modality Therapy for Esophageal Cancer: High-Dose Versus Standard-Dose Radiation Therapy , 2002 .
[27] R. Ginsberg,et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] J. Cooper,et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. , 1999, JAMA.
[29] J. Cooper,et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. , 1992, The New England journal of medicine.
[30] H. Kato,et al. ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography for Evaluating the Response to Neoadjuvant Chemotherapy in Advanced Esophageal Cancer. , 2016, Anticancer research.
[31] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[32] S. Law. Chemoradiotherapy - panacea for esophageal cancer? Commentary for 'Chemoradiotherapy of locally advanced esophageal cancer. Long-term follow-up of a prospective randomized trial (RTOG 85-01)' , 1999 .